公开(公告)号：WO2018094253A1

公开(公告)日：2018-05-24

申请号：PCT/US2017/062375

申请日：2017-11-17

Applicant: PACIRA PHARMACEUTICALS, INC.

Inventor： GARCIA, Louie, Daniel ,  SCHUTT, Ernest, George ,  KHARITONOV, Vladimir ,  KURZ, Stephanie ,  LOS, Kathleen Dunne, Albright ,  STONE, Katherine

IPC: C07D417/12 ,  B02C23/06

Abstract: Embodiments of the present disclosure are related to multivesicular liposome formulations encapsulating zinc meloxicam complex microparticles. Methods of making the zinc meloxicam complex microparticles and administering the zinc meloxicam complex microparticles encapsulated in multivesicular liposome formulations and their use as medicaments are also provided.

公开(公告)号：WO2012058483A1

公开(公告)日：2012-05-03

申请号：PCT/US2011/058169

申请日：2011-10-27

Applicant: PACIRA PHARMACEUTICALS, INC. ,  GARCIA, Louie, Daniel ,  ZHU, Liangjin ,  LAMBERT, William, Joseph ,  PATOU, Gary

Inventor： GARCIA, Louie, Daniel ,  ZHU, Liangjin ,  LAMBERT, William, Joseph ,  PATOU, Gary

IPC: A61P29/00 ,  A61K9/127

CPC classification number: A61K9/1272 ,  A61K9/127 ,  A61K9/1277 ,  A61K9/1278 ,  A61K31/196 ,  A61K31/407 ,  A61K31/5415

Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.

Abstract translation: 公开了包含多泡脂质体和一种或多种非甾体抗炎药物的制剂，其在维持或改善功效的同时使未包封的非甾体抗炎药物的副作用最小化。 还提供了制备和施用包含多泡脂质体和一种或多种非甾体抗炎药的制剂及其用作药物的方法。

公开(公告)号：WO2011143484A1

公开(公告)日：2011-11-17

申请号：PCT/US2011/036328

申请日：2011-05-12

Applicant: PACIRA PHARMACEUTICALS, INC. ,  GARCIA, Louie, Daniel ,  GIBSON, Lois ,  LAMBERT, William ,  LI, Benjamin ,  ZHU, Liangjin

Inventor： GARCIA, Louie, Daniel ,  GIBSON, Lois ,  LAMBERT, William ,  LI, Benjamin ,  ZHU, Liangjin

IPC: A61K9/127 ,  A61P35/00 ,  A61K31/519 ,  A61P37/00

CPC classification number: A61K9/127 ,  A61K9/0019 ,  A61K31/198 ,  A61K31/25 ,  A61K31/519 ,  A61K31/575 ,  A61K31/685 ,  A61K2300/00

Abstract: Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a C max of MTX between 5% and 50% of the C max of an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are methods of treating autoimmune diseases and cancer by administering these formulations of MTX.

Abstract translation: 公开了包含多泡脂质体和MTX的制剂，其施用导致MTX的立即释放剂型C max的5％至50％的5％至50％的C max，其持续时间为约1至约30 天。 还公开了通过施用MTX的这些制剂来治疗自身免疫性疾病和癌症的方法。